BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 10435880)

  • 1. Effects of cholinergic muscarinic blockade on growth hormone responses to growth hormone-releasing hormone in uraemic patients.
    Díez JJ; Iglesias P; Aguilera A; Bajo MA; Selgas R
    Nephrol Dial Transplant; 1999 Jul; 14(7):1704-9. PubMed ID: 10435880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholinergic modulation of growth hormone responses to growth hormone-releasing hormone in uraemic patients on peritoneal dialysis.
    Díez JJ; Iglesias P; Selgas R; Bajo MA; Aguilera A
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):587-93. PubMed ID: 11106919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acetylcholine does not play a major role in mediating the endocrine responses to ghrelin, a natural ligand of the GH secretagogue receptor, in humans.
    Broglio F; Gottero C; Benso A; Prodam F; Casanueva FF; Dieguez C; van der Lely AJ; Deghenghi R; Arvat E; Ghigo E
    Clin Endocrinol (Oxf); 2003 Jan; 58(1):92-8. PubMed ID: 12519418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of withdrawal of somatostatin plus GH-releasing hormone as a stimulus of GH secretion in obesity.
    Alvarez P; Isidro L; Leal-Cerro A; Casanueva FF; Dieguez C; Cordido F
    Clin Endocrinol (Oxf); 2002 Apr; 56(4):487-92. PubMed ID: 11966741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth hormone responses to growth hormone-releasing hormone and clonidine before and after erythropoietin therapy in CAPD patients.
    Díez J; Iglesias P; Sastre J; Méndez J; Selgas R; Gómez-Pan A
    Nephron; 1996; 74(3):548-54. PubMed ID: 8938679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth hormone responses to growth hormone-releasing hormone and hexarelin in fed and fasted dogs: effect of somatostatin infusion or pretreatment with pirenzepine.
    Rigamonti AE; Marazzi N; Cella SG; Cattaneo L; Müller EE
    J Endocrinol; 1998 Feb; 156(2):341-8. PubMed ID: 9518881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholinergic involvement in the growth hormone releasing hormone-induced growth hormone release: studies in normal and acromegalic subjects.
    Massara F; Ghigo E; Demislis K; Tangolo D; Mazza E; Locatelli V; Müller EE; Molinatti GM; Camanni F
    Neuroendocrinology; 1986; 43(6):670-5. PubMed ID: 3093909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of cholinergic blockade on nocturnal thyrotropin and growth hormone (GH) secretion in type I diabetes mellitus: further evidence supporting somatostatin's involvement in GH suppression.
    Goñi MJ; Monreal M; Goñi F; Sopena M; Gil MJ; Moncada E; Salvador J
    Metabolism; 1997 Nov; 46(11):1305-11. PubMed ID: 9361690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation and neuroregulatory control of growth hormone secretion.
    Ogilvy-Stuart AL; Wallace WH; Shalet SM
    Clin Endocrinol (Oxf); 1994 Aug; 41(2):163-8. PubMed ID: 7923820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism.
    Cordido F; Fernandez T; Martinez T; Peñalva A; Peinó R; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1998 Dec; 83(12):4350-4. PubMed ID: 9851776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone (GH) responses to GH-releasing hormone alone or combined with arginine in patients with adrenal incidentaloma: evidence for enhanced somatostatinergic tone.
    Terzolo M; Bossoni S; Alí A; Doga M; Reimondo G; Milani G; Peretti P; Manelli F; Angeli A; Giustina A
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1310-5. PubMed ID: 10720081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In obesity the somatotrope response to either growth hormone-releasing hormone or arginine is inhibited by somatostatin or pirenzepine but not by glucose.
    Maccario M; Procopio M; Grottoli S; Oleandri SE; Razzore P; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3774-8. PubMed ID: 8530634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.
    Arvat E; Maccario M; Di Vito L; Broglio F; Benso A; Gottero C; Papotti M; Muccioli G; Dieguez C; Casanueva FF; Deghenghi R; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1169-74. PubMed ID: 11238504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.
    Ghigo E; Gianotti L; Arvat E; Ramunni J; Valetto MR; Broglio F; Rolla M; Cavagnini F; Müller EE
    J Clin Endocrinol Metab; 1999 Jan; 84(1):285-90. PubMed ID: 9920097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of growth hormone-releasing hormone and somatostatin to decreased growth hormone secretion in elderly men.
    Soule SG; Macfarlane P; Levitt NS; Millar RP
    S Afr Med J; 2001 Mar; 91(3):254-60. PubMed ID: 11291426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence that alpha 2-adrenergic pathways play a major role in growth hormone (GH) neuroregulation: alpha 2-adrenergic agonism counteracts the inhibitory effect of muscarinic cholinergic receptor blockade on the GH response to GH-releasing hormone, while alpha 2-adrenergic blockade diminishes the potentiating effect of increased cholinergic tone on such stimulation in normal men.
    Devesa J; Diaz MJ; Tresguerres JA; Arce V; Lima L
    J Clin Endocrinol Metab; 1991 Aug; 73(2):251-6. PubMed ID: 1677361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of cholinergic muscarinic antagonist pirenzepine on GH response to GHRH 1-40 in patients with anorexia nervosa.
    Rolla M; Andreoni A; Belliti D; Ferdeghini M; Cristofani R; Müller EE
    Endocrinol Exp; 1990 Mar; 24(1-2):195-204. PubMed ID: 2113857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for integrity of the growth hormone/insulin-like growth factor-1 axis in patients with severe head trauma during rehabilitation.
    Bondanelli M; Ambrosio MR; Margutti A; Boldrini P; Basaglia N; Franceschetti P; Zatelli MC; Degli Uberti EC
    Metabolism; 2002 Oct; 51(10):1363-9. PubMed ID: 12370860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased growth hormone response to growth hormone releasing hormone induced by erythropoietin in uraemic patients.
    Cantalamessa L; Cremagnani L; Orsatti A; Vigna L; Buccianti G
    Clin Endocrinol (Oxf); 1991 Jan; 34(1):85-9. PubMed ID: 2004477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans.
    Gianotti L; Maccario M; Lanfranco F; Ramunni J; Di Vito L; Grottoli S; Muller EE; Ghigo E; Arvat E
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3604-8. PubMed ID: 11061509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.